Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody: Long‐Term Safety and Efficacy in Patients With Rheumatoid Arthritis

OBJECTIVE: Mavrilimumab, a human monoclonal antibody, targets granulocyte–macrophage colony‐stimulating factor receptor α. We undertook to determine the long‐term safety and efficacy of mavrilimumab in rheumatoid arthritis patients in 2 phase IIb studies (1071 and 1107) and in 1 open‐label extension...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arthritis Rheumatol
Autors principals: Burmester, Gerd R., McInnes, Iain B., Kremer, Joel M., Miranda, Pedro, Vencovský, Jiří, Godwood, Alex, Albulescu, Marius, Michaels, M. Alex, Guo, Xiang, Close, David, Weinblatt, Michael
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Rheumatoid Arthritis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947536/
https://ncbi.nlm.nih.gov/pubmed/29361199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40420
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars